Bavarian Nordic

Bavarian Nordic Improving and saving lives through innovative vaccines is at the heart of what we do at Bavarian Nordic. For us, it is all about improving and saving lives.

We are a fully integrated vaccine company, focused on the development, manufacturing, and commercialization of our vaccines Improving and saving lives through innovative vaccines is at the heart of what we do in Bavarian Nordic, and we have more than 25 years of experience in developing life-saving vaccines. We are a fully integrated vaccine company focused on the development, manufacturing and co

mmercialization of our vaccines. We are a global leader in smallpox and mpox vaccines, which have been developed through our long-standing partnership with the U.S. Government to enhance the public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. Our values – our Bavarian Nordic DNA, as we call it – is what guides our actions. We act as persistent pioneers, we are embracing change, we value being boosted by the team, and we believe in protecting lives every day. If that is also a part of your DNA, we invite you to join us in Bavarian Nordic! We are a global team of more than 1,400 dedicated people with diverse backgrounds and viewpoints who are bound together by our commitment to protect lives every day. We believe in creating an inclusive and flexible workplace with a strong focus on personal and professional development, because we need each other to take things further. We operate in a world in constant flux and always explore new opportunities. So, if you are open-minded and have the willpower to succeed, we might just be a perfect fit. See your career opportunities at www.bavarian-nordic.com/careers

13/05/2026

Our Q1 2026 results are out – and they confirm the strength of our business. 👇

🌍 Travel Health delivered strong growth, driven by sustained demand and our continued focus on organic growth in existing markets

🛡️ Public Preparedness performed in line with expectations in a more normalized environment following years of outbreak‑driven demand

Within Travel Health, our chikungunya vaccine continues to gain traction, while our rabies vaccine remains a key growth driver.

📈 Following a new contract from the US government for the production and supply of smallpox vaccines, we have upgraded our full‑year guidance to DKK 5,500–5,700 million and an EBITDA margin of approximately 28%.

We are proud of the trust placed in our company and our vaccines. That trust from customers, governments and partners reflects the continued need for our vaccines – and the role we play in helping safeguard communities against emerging threats.

Explore the key Q1 2026 figures in the video below.

27/04/2026

This week, we join the global community in marking World Immunization Week.

Under the World Health Organization theme "For every generation, vaccines work", this week highlights how vaccines continue to protect people, families and communities, and why they remain essential to the future of public health.

Hear from our colleagues, watch the video and join the conversation.

Adresse

Hellerup

Internet side

Underretninger

Vær den første til at vide, og lad os sende dig en email, når Bavarian Nordic sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Genveje

Del

Type